1099 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author임형신-
dc.date.accessioned2018-05-31T04:12:08Z-
dc.date.available2018-05-31T04:12:08Z-
dc.date.issued2017-02-
dc.identifier.citationARCHIVES OF PHARMACAL RESEARCH, v. 40, No. 2, Page. 146-151en_US
dc.identifier.issn0253-6269-
dc.identifier.issn1976-3786-
dc.identifier.urihttps://link.springer.com/article/10.1007/s12272-016-0874-x-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/71767-
dc.description.abstractThe proteins p150(Sal2) (product of SALL2) and p53 share growth arrest and pro-apoptotic functions by independently inducing p21(Cip1/Waf1) and BAX, and both proteins are targeted by the human papilloma virus E6 protein, leading to blockage of growth arrest in infected cells. Loss of both p53 and Sall2 in mice causes significantly higher mortality and metastasis rates compared with p53 single mutant mice. Therefore, p150(Sal2) seems to have strong potential as a novel cancer biomarker for early diagnosis and risk prediction. Loss of SALL2 expression is observed in many cases of human serous ovarian carcinoma, whereas normal ovarian epithelial cells maintain high levels of the p150(Sal2) protein, supporting an important tumor suppressive role for p150(Sal2) in the human ovary. In contrast, p150(Sal2) is a transcription factor required to convert differentiated glioblastoma cells into stem-like tumor-propagating cells, suggesting that its functional roles are dependent on tissue types and cellular context. The function of p150(Sal2) in normal and diseased cells and possible therapeutic approaches are discussed in this review.en_US
dc.description.sponsorshipThis work was supported by the National Science Foundation (to CKS; NSF CBET-1504174) and the research fund of Hanyang University (HY-2014-N) to HY.en_US
dc.language.isoen_USen_US
dc.publisherPHARMACEUTICAL SOC KOREAen_US
dc.subjectOvarian carcinomaen_US
dc.subjectGlioblastomaen_US
dc.subjectMouse polyomavirusen_US
dc.subjectHuman papillomavirusen_US
dc.subjectp150(sal2)en_US
dc.subjectp53en_US
dc.subjectp21(Cip1/Waf1)en_US
dc.subjectBAXen_US
dc.subjectTUMOR-SUPPRESSOR GENEen_US
dc.subjectEXPRESSIONen_US
dc.subjectTRANSCRIPTIONen_US
dc.subjectCANCERen_US
dc.subjectONCOGENEen_US
dc.subjectPROMOTERen_US
dc.subjectPROTEINen_US
dc.subjectCELLSen_US
dc.subjectREGULATORen_US
dc.titleRoles of SALL2 in tumorigenesisen_US
dc.typeArticleen_US
dc.relation.no2-
dc.relation.volume40-
dc.identifier.doi10.1007/s12272-016-0874-x-
dc.relation.page146-151-
dc.relation.journalARCHIVES OF PHARMACAL RESEARCH-
dc.contributor.googleauthorSung, Chang K-
dc.contributor.googleauthorYim, Hyungshin-
dc.relation.code2017007152-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhsyim-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE